PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms...
Date First Received: October 3, 2007
Last Updated: October 4, 2007
Verified by: Samsung Medical Center, March 2006
Clinical Trial Phase: N/A | Start Date: March 2006
Overall Status: Recruiting
Brief Summary
Official Title: “Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms”
Condition Keyword(s):
Intervention(s):
PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.
Study Type: Interventional
Study Design: Diagnostic, Open Label, Parallel Assignment
Intervention(s) in this Clinical Trial
- Drug: Proton pump inhibitor (rabeprazole)
- Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
Outcome Measures for this Clinical Trial
Primary Measures
- Symptom responders after PPI trials
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients with extraesophageal manifestation symptoms of GERD
Exclusion Criteria:
- laryngeal, pharyngeal, liver, lung, renal, or hematological disorders
- a history of gastrointestinal surgery, and a history of connective tissue disorders.
- patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 75 Years
Clinical Trial Sponsor Information
Lead Sponsor: Samsung Medical Center
Overall Clinical Trial Officials and Contacts
Poong-Lyul Rhee, MD. Ph.D Principal Investigator Samsung Medical Center, Sungkyunkwan University School of Medicine
Overall Contact: Tae ggon Kim +82-2-3410-2975 tggo.kim@samsung.com
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00539786
Study ID Number: 2006-03-071
ClinicalTrials.gov Identifier: NCT00539786
Health Authority: Korea: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
